Compare Alcon AG (ALC) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Equinor ASA — how do they compare? Alcon AG trades at $73.59 (market cap $36.44B), while Equinor ASA trades at $41.01 (market cap $97.58B). The key difference: Equinor ASA is far larger — about 2.7× Alcon AG's market cap, and Equinor ASA pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| ALC | EQNR | |
|---|---|---|
Market Cap | $36.44B | $97.58B |
Sector | Health | Energy |
52-Week High | $90.12 | $42.40 |
52-Week Low | $62.02 | $22.41 |
Enterprise Value | $40.28B | $106.28B |
Dividend Yield | 0.48% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.525, down 0.14% on the day, with a bullish technical signal from moving averages and positive analyst sentiment. Recent Q2 2026 earnings beat estimates, with revenue of $10.4 billion in 2025 and a net income margin of 5.92%. The company raised its 2026 profitability outlook, citing tariff relief and strong product launches.
The stock offers a 17.9% upside to the consensus price target of $86.67, supported by bullish analyst ratings and improving cash flow trends. Key risks include elevated P/E valuation at 57.52 and potential macroeconomic pressures on medical device demand. Earnings growth and execution on new products remain critical for sustained momentum.
Equinor (EQNR) trades at $40.92, down slightly by 0.17% on the day, with strong technical momentum showing a bullish moving average signal. The company delivered mixed Q2 2026 earnings with a revenue beat but EPS miss, while maintaining robust cash flow generation and shareholder returns through dividends and buybacks. Recent news highlights strong quarterly performance driven by higher energy prices and production growth.
EQNR presents a compelling value case with attractive valuation multiples (P/E 11.09, EV/EBITDA 2.3) and solid profitability metrics (ROE 21.32%). However, declining profit margins from 19.29% in 2022 to 4.76% in 2025 and analyst caution (56.53% hold rating) suggest balanced risk-reward. The stock offers income potential with consistent dividends amid energy market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
